Published in J Cardiol on April 16, 2009
Disordered haematopoiesis and athero-thrombosis. Eur Heart J (2016) 0.85
Acute ST-segment elevation myocardial infarction in a young patient with essential thrombocythemia: a case with long-term follow-up report. J Blood Med (2014) 0.75
Very Late Stent Thrombosis in a Drug-Eluting Stent due to Interruption of Anti-Platelet Agents in Patients With Acute Myocardial Infarction and Thrombocytosis. Korean Circ J (2011) 0.75
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol (2003) 2.52
Serum lysophosphatidic acid is produced through diverse phospholipase pathways. J Biol Chem (2002) 2.42
Electrophysiologic properties of pulmonary veins assessed using a multielectrode basket catheter. J Am Coll Cardiol (2004) 1.85
Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol (2002) 1.84
Reduction of P-wave duration and successful pulmonary vein isolation in patients with atrial fibrillation. J Cardiovasc Electrophysiol (2007) 1.82
Expression of human apoAII in transgenic rabbits leads to dyslipidemia: a new model for combined hyperlipidemia. Arterioscler Thromb Vasc Biol (2009) 1.64
Addition of a Nitric Oxide Donor to an Angiotensin II Type 1 Receptor Blocker May Cancel Its Blood Pressure-Lowering Effects. Int Heart J (2015) 1.54
Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol (2003) 1.54
Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res (2012) 1.51
Association between hypertension and coronary artery disease as assessed by coronary computed tomography. J Clin Hypertens (Greenwich) (2011) 1.49
Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. J Cardiol (2012) 1.48
Impact of glycemic control on the clinical outcome in diabetic patients with percutaneous coronary intervention--from the FU-registry. Circ J (2011) 1.45
A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). Circ J (2010) 1.45
Lifestyle changes through the use of delivered meals and dietary counseling in a single-blind study. The STYLIST study. Circ J (2012) 1.44
Novel molecular imaging of atherosclerosis with gallium-68-labeled apolipoprotein A-I mimetic peptide and positron emission tomography. Circ J (2013) 1.43
Associations between metabolic factors and coronary plaque growth or arterial remodeling as assessed by intravascular ultrasound in patients with stable angina. Hypertens Res (2008) 1.42
Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep (2008) 1.40
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res (2004) 1.40
Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem (2006) 1.38
Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis (2006) 1.33
Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest (2010) 1.26
Assessment of optimal condylar position with limited cone-beam computed tomography. Am J Orthod Dentofacial Orthop (2009) 1.22
Molecular analysis of the structure and function of the angiotensin II type 1 receptor. Hypertens Res (2003) 1.15
Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol (2007) 1.12
Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun (2002) 1.12
Coronary-pulmonary artery fistula with anomalous vessels arising from the right coronary sinus detected by 64-MDCT. Intern Med (2009) 1.11
HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol (2008) 1.11
High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler Thromb Vasc Biol (2003) 1.09
Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst (2010) 1.08
Human CD1 dimeric proteins as indispensable tools for research on CD1-binding lipids and CD1-restricted T cells. J Immunol Methods (2009) 1.07
Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J Biol Chem (2005) 1.07
Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol (2007) 1.06
Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARγ/LXRα pathway: findings from in vitro and ex vivo studies. Atherosclerosis (2011) 1.06
Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J Cardiovasc Electrophysiol (2003) 1.04
A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects. Hypertens Res (2010) 1.03
Relationship between masticatory function and internal structure of the mandible based on computed tomography findings. Am J Orthod Dentofacial Orthop (2005) 1.00
Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). Am J Cardiol (2010) 1.00
Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension (2003) 1.00
Gastric ulcer associated with cytomegalovirus in an immunocompetent patient: method for diagnosis. Case Rep Gastroenterol (2012) 0.99
Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation. Hypertens Res (2004) 0.98
Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection. J Gastroenterol Hepatol (2003) 0.98
Antiarrhythmogenic effect of reconstituted high-density lipoprotein against ischemia/reperfusion in rats. J Am Coll Cardiol (2008) 0.93
Clinical significance of flow-mediated dilation, brachial intima-media thickness and pulse wave velocity in patients with and without coronary artery disease. Circ J (2012) 0.93
CXCR3 chemokine receptor-plasma IP10 interaction in patients with coronary artery disease. Circ J (2003) 0.92
Association between coronary artery calcification score as assessed by multi-detector row computed tomography and upstroke time of pulse wave. Intern Med (2007) 0.92
Correlation of high density lipoprotein (HDL)-associated sphingosine 1-phosphate with serum levels of HDL-cholesterol and apolipoproteins. Atherosclerosis (2005) 0.91
Calcification of the medial layer of the internal thoracic artery in diabetic patients: relevance of glycoxidation. J Vasc Res (2003) 0.91
Ezetimibe, a selective inhibitor of the transport of cholesterol. Intern Med (2008) 0.90
Splicing variant of Cdc42 interacting protein-4 disrupts beta-catenin-mediated cell-cell adhesion: expression and function in renal cell carcinoma. Biochem Biophys Res Commun (2005) 0.90
Statins induce the regression of left ventricular mass in patients with angina. Circ J (2004) 0.90
Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J (2007) 0.90
Apolipoprotein E interrupts interleukin-1beta signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2007) 0.89
Chymase inhibitor improves survival in hamsters with myocardial infarction. J Cardiovasc Pharmacol (2003) 0.89
Reperfusion-induced arrhythmias are suppressed by inhibition of the angiotensin II type 1 receptor. Cardiology (2003) 0.89
Free fatty acid causes leukocyte activation and resultant endothelial dysfunction through enhanced angiotensin II production in mononuclear and polymorphonuclear cells. Hypertension (2010) 0.89
Left ventricular pseudoaneurysm following acute myocardial infarction. Intern Med (2006) 0.89
Reconstituted high-density lipoprotein attenuates postinfarction left ventricular remodeling in rats. Atherosclerosis (2008) 0.88
Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor/fetal liver kinase-1/NO pathway. Hypertens Res (2005) 0.88
Pilsicainide for atrial fibrillation. Drugs (2006) 0.88
Comparison of the efficacy and safety of single-pill fixed-dose combinations of losartan/hydrochlorothiazide and valsartan/hydrochlorothiazide in patients with hypertension (SALT-VAT study). Intern Med (2011) 0.87
Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation. Atherosclerosis (2006) 0.87
Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis (2005) 0.87
Assessment of optimal condylar position in the coronal and axial planes with limited cone-beam computed tomography. J Prosthodont (2011) 0.87